Key result
Intracoronary epinephrine reduced major adverse cardiovascular events at 1 year compared to adenosine (11.3% vs 26.7%, p<0.01) in patients with refractory no-reflow phenomenon during primary PCI.
Why the study?
There has been no head-to-head comparison of intracoronary epinephrine to adenosine for managing the refractory no-reflow phenomenon during primary PCI.
Does intracoronary epinephrine improve angiographic outcomes and reduce MACE compared to adenosine in STEMI patients with refractory no-reflow during primary PCI?
Cohort (n=156)
No
Does intracoronary epinephrine improve angiographic outcomes and reduce MACE compared to adenosine in STEMI patients with refractory no-reflow during primary PCI?
Absolute Event Rate: 11.3% vs 26.7%
p-value: p=<0.01
Intracoronary epinephrine may be an effective and safe alternative to adenosine for managing refractory no-reflow during primary PCI, potentially offering better long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
May support epinephrine in refractory no-reflow; leaves open need for randomized confirmation.
Frere et al. (2022) conducted a cohort in Refractory no-reflow phenomenon during primary PCI for STEMI (n=156). Intracoronary epinephrine vs. Intracoronary adenosine was evaluated on Major adverse cardiovascular events (MACE) at 1 year (p=<0.01). Intracoronary epinephrine reduced major adverse cardiovascular events at 1 year compared to adenosine (11.3% vs 26.7%, p<0.01) in patients with refractory no-reflow phenomenon during primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: